Home > Healthcare > Medical Devices > Surgical Devices > Embolic Protection Devices Market

Embolic Protection Devices Market Size - By Product (Distal Occlusion Systems, Proximal Occlusion Systems, Distal Filters), By Application (Cardiovascular Disease, Neurovascular Disease, Peripheral Disease), By Material (Nitinol, Polyurethane), By End-use - Global Forecast, 2023 - 2032

  • Report ID: GMI2417
  • Published Date: Jul 2023
  • Report Format: PDF

Embolic Protection Devices Market Size

Embolic Protection Devices Market was worth USD 1.4 billion in 2022. Driven by the increasing number of cardiovascular diseases (CVDs) globally, the industry is estimated to witness over 8.5% CAGR between 2023 and 2032. According to the WHO, CVDs are the leading cause of death globally, accounting for 17.9 million deaths in 2022.

 

Embolic Protection Devices Market

The growing number of patients suffering from cardiac problems is fueling the need for percutaneous coronary interventions and the subsequent rise in demand for interventional cardiology & peripheral vascular devices. As per CDC, coronary artery disease is the most prevalent kind of heart disease in the U.S. The growing prevalence of CAD is contributing to rising product demand. Additionally, embolic protection devices provide the most effective, evidence-based method for decreasing significant adverse cardiovascular events and periprocedural myocardial infarction during SVG procedures, which will favor their adoption through 2032.

 

Embolic Protection Devices Market Growth Drivers & Restraints

The market is poised to gain significant momentum attributed to the favorable reimbursement scenario across American nations and the introduction of new advanced embolic protection devices. However, the availability of cheaper alternatives to embolic protection devices may lead to sluggish growth. Besides, the high cost of these devices may adversely impact product adoption rate since healthcare professionals in developing nations prefer inexpensive medical equipment.

 

COVID-19 Impact

The COVID-19 pandemic posed significant obstacles to PCI protocols. A remarkable surge in COVID-19 infections led to a considerable decline in percutaneous coronary intervention operations and peripheral interventions. According to the European Heart Journal, the number of cardiac surgeries in the UK registered a shortfall of more than 45,000 procedures due to the pandemic. Furthermore, logistical delays caused by lockdowns and delayed production activities impacted the product supply chain, resulting in temporary shortages and slowing down the market expansion.
 

Embolic Protection Devices Market Trends

Technological improvements and breakthroughs in embolic protection devices are expected to boost the business outlook over the next ten years. Distal occlusion devices, distal filter devices, and proximal occlusion/flow-reversal devices, among other innovations, are intended to avoid embolic debris during endovascular operations. For instance, Medtronic's Mo. Ma Ultra proximal cerebral protection device uses a double-occlusion balloon system to guarantee proximal embolic protection before passing a carotid lesion. Furthermore, continuous R&D targeted at enhancing the efficacy, safety, and ease of use of these devices will contribute to their increased acceptance.

 

Embolic Protection Devices Market Analysis

Embolic Protection Devices Market Size, By Product,

The embolic protection devices market from distal filters segment is projected to reach USD 1.9 billion by 2032, depicting over 8.5% CAGR from 2023 to 2032. The availability of a wide range of specifications and the surging usage of distal filters are driving industry expansion. The fundamental advantage of using distal filters versus proximal occlusion devices is that they keep blood flowing while capturing big material. Furthermore, such filters retain an antegrade circulation of blood and are simple to use, thus, propelling market revenue.

 

Embolic Protection Devices Market Share, By Application,

The embolic protection devices market share from cardiovascular disease segment generated over USD 540 million in revenue in 2022 and is estimated to reach USD 1.3 billion by 2032. The global prevalence of cardiovascular disorders is attributable to segment expansion. According to CDC, heart disease is among the leading cause of death in the United States, with one person dying every 33 seconds from cardiovascular disease. The increasing demand for interventional methods to address these illnesses will increase the demand for effective cardiovascular devices to reduce the risk of consequences. The growing use of embolic protection devices in transcatheter aortic valve replacement, percutaneous coronary intervention, and other cardiac procedures will foster segment demand.

 

U.S. Embolic Protection Devices Market Size,

North America held over 35.5% share of the embolic protection devices market revenue in 2022 and is projected to be worth USD 1 billion by 2032. The rising prevalence of cardiovascular and neurovascular diseases in the region is driving market trends. Additionally, the strong foothold of major industry players, increasing incidence of obesity, lifestyle patterns, and unhealthy dietary habits will positively influence the regional market growth. According to a study published in the Harvard T.H. Chan School of Public Health, nearly two out of three or 69% adults in the U.S. are obese or overweight. Moreover, the ongoing R&D efforts, in line with the introduction of innovative and more effective embolic protection devices, will boost regional market gains.

 

Embolic Protection Devices Market Share

Some of the major players operating in the embolic protection devices market are

  • Transverse Medical, Inc.
  • Abbott Laboratories
  • Cardinal Health
  • Allium Medica
  • Edwards Lifesciences Corporation
  • W. L. Gore & Associates (Gore Medical)
  • Contego Medical, LLC
  • Keystone Heart
  • Medtronic
  • Metactive Medical
  • Boston Scientific Corporation
  • Innovative Cardiovascular Solutions, LLC.

     

Embolic Protection Devices Market News

  • In September 2022, Boston Scientific Corporation revealed the results from the clinical trial conducted on the PROTECTED TAVR for assessing the SENTINEL Cerebral Protection System, designed to capture and eliminate embolic debris from the replacement of the transcatheter aortic valve before it can reach the brain and potentially cause a stroke. Such advancements helped to retain the company's brand image while also extending the company's customer portfolio.       
     

Embolic protection devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report


By Product (USD Million)

  • Distal occlusion systems
  • Proximal occlusion systems
  • Distal filters

By Application (USD Million)

  • Cardiovascular disease
  • Neurovascular disease
  • Peripheral disease

By Material (USD Million)

  • Nitinol
  • Polyurethane

By End-use (USD Million)

  • Hospitals
  • Ambulatory surgical centers
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Switzerland
    • The Netherlands
    • Denmark
    • Poland
    • Sweden
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • New Zealand
    • Thailand
    • Vietnam
    • Indonesia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Chile
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Turkey

 

Authors: Mariam Faizullabhoy , Shishanka Wangnoo

Frequently Asked Questions (FAQ) :

Embolic protection devices market was valued at USD 1.4 billion in 2022 and is poised to exhibit over 8.5% CAGR from 2023 to 2032 owing to the rising prevalence of cardiovascular diseases (CVDs) globally.

The embolic protection devices market from the distal filters segment is estimated to grow at above 8.5% CAGR over 2023-2032 and is expected to generate USD 1.9 billion by 2032 driven by the availability of a wide range of specifications and the surging usage of distal filters.

North America amassed over 35.5% share of the embolic protection devices market in 2022 and is foreseen to be valued at USD 1 billion by 2032 attributed to the rising prevalence of cardiovascular and neurovascular diseases in the region.

Some of the top players engaged in the industry are Transverse Medical, Inc., Abbott Laboratories, Cardinal Health, Allium Medica, Edwards Lifesciences Corporation, W. L. Gore & Associates (Gore Medical), Contego Medical, LLC, Keystone Heart, Medtronic, Metactive Medical, Boston Scientific Corporation, and Innovative Cardiovascular Solutions, LLC.

Embolic Protection Devices Market Scope

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 12
  • Tables & Figures: 349
  • Countries covered: 30
  • Pages: 210
 Download PDF